Tirzepatide Reduces Mortality by 62% in Patients Who Undergo PCI Compared to Dulaglutide Previous studies have demonstrated that tirzepatide outperforms dulaglutide, a GLP-1 receptor agonist that targets only GLP-1 receptors, by reducing major adverse cardiovascular events (MACE), weight, and HbA1c levels
Since kidney function is reduced during AKI, activation of the urea cycle and subsequent urea generation together lead to a substantial rise in BUN 14,35
Although the CIs were wide because of the small number of events in subgroups, point estimates showed that the combination of GLP-1RAs and SGLT2is tended to reduce the incidence of HHF more than either alone
Shima Hadidchi MD Family Practice Clinic, we are committed to helping our patients achieve their health goals through personalized care and evidence-based treatment options
Skin prick testing has limited value as type 1 allergic reactions are less common
GLP-1 Receptor Activation: Suppresses appetite through hypothalamic pathways Slows gastric emptying Enhances insulin secretion GIP Receptor Activation: Amplifies GLP-1 satiety effects Improves insulin sensitivity May directly affect fat cell metabolism Glucagon Receptor Activation: Increases energy expenditure (metabolic rate) Promotes fat breakdown (lipolysis) May prevent metabolic adaptation The Advantage: Single molecule means simpler manufacturing, potentially easier regulatory approval, and all three pathways activated with every dose